{"entity":{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","aka":["Cephalon","Actavis Inc.","Actavis","Teva Branded Pharmaceutical Products R&D, Inc.","Barr Laboratories","Watson Pharmaceuticals"],"tldr":"Teva is the world's largest generic medicines company; its branded oncology products include omacetaxine (Synribo) for resistant chronic myeloid leukaemia, arsenic trioxide (Trisenox), bendamustine (Bendeka) and the G-CSF products Granix and Lonquex.","summary":"Teva Pharmaceuticals, based in Tel Aviv and listed as TEVA, is the world's largest generic medicines company; its branded oncology products include omacetaxine, sold as Synribo, for resistant chronic myeloid leukaemia, arsenic trioxide as Trisenox, bendamustine as Bendeka and the G-CSF products Granix and Lonquex. It acquired Cephalon in 2011, gaining Trisenox, Treanda and Synribo, and markets tbo-filgrastim as Granix in the United States and lipegfilgrastim as Lonquex in Europe, alongside the largest generic oncology injectables portfolio worldwide. OnCo links it to filgrastim, lipegfilgrastim and omacetaxine. Whether the largest generic injectables maker can keep supply steady through the recurring shortages that hit chemotherapy is the question its scale invites. Each product has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tevapharm.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["arsenic-trioxide","epoetin-theta"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tel Aviv","country":"IL","companyType":"pharma","website":"https://www.tevapharm.com","ticker":"TEVA","investors":[],"funding":[]},"route":"/companies/teva/","neighbours":{"drug":[{"id":"arsenic-trioxide","kind":"drug","name":"Arsenic trioxide","route":"/drugs/arsenic-trioxide/"},{"id":"epoetin-theta","kind":"drug","name":"Epoetin theta","route":"/drugs/epoetin-theta/"},{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/"},{"id":"omacetaxine","kind":"drug","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/"}],"technology":[{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/"},{"id":"oral-solid-dose-manufacturing","kind":"technology","name":"Oral solid dose manufacturing (tablets and capsules)","route":"/technologies/oral-solid-dose-manufacturing/"},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/"}],"trial":[{"id":"xm22-03","kind":"trial","name":"XM22-03","route":"/trials/xm22-03/"}],"paper":[{"id":"paper-xm22-03-bondarenko-bmc-cancer-2013","kind":"paper","name":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)","route":"/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/"}]}}